Skip to main content
Premium Trial:

Request an Annual Quote

Lilly Licenses Software From Pangea, Pharsight

Premium

INDIANAPOLIS--Eli Lilly has licensed Pangea's bioinformatics software, including the GeneWorld application, GeneThesaurus data subscription service, and its information management environment, Pulse, for use in Lilly's genomics and target validation efforts. Marie Martin, Pangea's director of marketing communications, told BioInform that the sale of the three tools combined optimizes the power of the software maker's core offerings.

GeneWorld is an automated high-throughput analysis application that enables researchers to access, annotate, and analyze large volumes of public and proprietary sequence data. GeneThesaurus is a data subscription service that provides a unified data source from multiple public gene and protein sequence and protein structure databases.

Pangea said Pulse is an information management environment that enables the bioinformatics developer to extend the functionality of an application.

In another deal, Lilly's clinical pharmacology/pharmacokinetic division purchased Pharsight's modeling and analysis software to aid research and development. The pharmaceutical company will deploy Pharsight's WinNonlin-Pro for modeling and analysis in targeted disease areas, including central nervous system and related diseases, endocrine diseases, infectious diseases, cancer, and cardiovascular diseases.

Richard Bergstrom, a senior research scientist for Lilly, said the software's ability to integrate large amounts of data and to provide modeling and analysis based on that information will enable the company to determine more efficiently the rate at which new drugs are absorbed, distributed, and eliminated by the body.

Filed under

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.